 "Claris Life up 20% as pharma companies eye its injectible biz")
Shares of Claris Lifesciences is locked in upper circuit of 20% at Rs 248, also its 52-week high on BSE, on reports that big pharmaceutical companies eyes the company’s injectables business for about Rs 3000 crore.
The Exchange said it has sought clarification from Claris Lifesciences with respect to news printed in The Economic Times on February 12, 2015 titled "Big Pharma Eyes Claris' Injectables Biz for Rs 3kcr". The reply is awaited.
“Several Indian pharma giants are competing with their global peers as the race to acquire the generic sterile injectables business of Ahmedabad-headquartered Claris Lifesciences,” the Economic Times report suggests.
Till 1216 hours, around 744,000 shares changed hands against an average 144,000 shares that were traded daily in past two weeks. There are pending buy orders for 271,774 shares on BSE.
The Exchange said it has sought clarification from Claris Lifesciences with respect to news printed in The Economic Times on February 12, 2015 titled "Big Pharma Eyes Claris' Injectables Biz for Rs 3kcr". The reply is awaited.
“Several Indian pharma giants are competing with their global peers as the race to acquire the generic sterile injectables business of Ahmedabad-headquartered Claris Lifesciences,” the Economic Times report suggests.
Till 1216 hours, around 744,000 shares changed hands against an average 144,000 shares that were traded daily in past two weeks. There are pending buy orders for 271,774 shares on BSE.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%